Abstract

The Effect of Herbal Medicine on Neuroblastoma Cell Line in Culture †

Buşra Şen 1,*, Pelin Toros 1, Pınar K. Sönmez 1, Mahmud Özkut 1, Şamil Öztürk 1, Fatih Çöllü 1, Sevinç Inan 2 and Ibrahim Tuğlu 1

1 Department of Histology & Embryology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45047, Turkey
2 Department of Histology & Embryology, Faculty of Medicine, İzmir Economy University, İzmir 35040, Turkey

* Correspondence: busrasen89@gmail.com; Tel.: +90-055-3034-2526
† Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November 2017.

Published: 15 November 2017

Abstract: Nowadays, interest in studies of traditional medicine in the world has gradually increased due to its potential to complement modern medicine, there are many phoytotherapautic plants that are used for the herbal medicine. Neuroblastoma (NB), is an embryonal tumor of the sympathetic nervous system, accounts for 15% of pediatric cancer deaths. In this study, we investigated to effect of several plants such as *Viscum album*, *Inula viscosa*, *Hypericum perforatum*, *Lysimachia nummularia*, *Pinus pinaster* and *Rubus caesius*, Oleocanthal, is popular for the antioxidant, anticancer, antimicrobial features on the mouse neuroblastoma cell line Na2B. The effects of plants on the Na2B cell lines and mesenchymal stem cell. Viability of the cells were investigated via MTT assay for IC50 level. eNOS and VEGF immunohistochemical staining were done to show the oxidative stress and angiogenesis respectively. Also TUNNEL assay were done for the apoptosis. The best results were taken from the *Inula viscosa* and *Rubus caesius*. These plants showed the greater eNOS expression and the lower VEGF expression and TUNNEL staining. Moreover these plants were not toxic for the mesenchymal stem cell. Our results showed that the effect of especially *Inula viscosa* and *Rubus caesius* have potential effect for cancer treatment.

Keywords: Na2B; phytotherapy; apoptosis; eNOS; VEGF

Conflicts of Interest: The authors declare no conflict of interest.

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).